Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119188840> ?p ?o ?g. }
- W3119188840 abstract "Abstract Background The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression. We now extend these findings with additional cohorts to further validate the adjusted MBDA score as a predictor of radiographic progression risk and compare its performance with that of other risk factors. Methods Four cohorts were analyzed: the BRASS and Leiden registries and the OPERA and SWEFOT studies (total N = 953). Treatments included conventional DMARDs and anti-TNFs. Associations of radiographic progression (ΔTSS) per year with the adjusted MBDA score, seropositivity, and clinical measures were evaluated using linear and logistic regression. The adjusted MBDA score was (1) validated in Leiden and SWEFOT, (2) compared with other measures in all four cohorts, and (3) used to generate curves for predicting risk of radiographic progression. Results Univariable and bivariable analyses validated the adjusted MBDA score and found it to be the strongest, independent predicator of radiographic progression (ΔTSS > 5) compared with seropositivity (rheumatoid factor and/or anti-CCP), baseline TSS, DAS28-CRP, CRP SJC, or CDAI. Neither DAS28-CRP, CDAI, SJC, nor CRP added significant information to the adjusted MBDA score as a predictor, and the frequency of radiographic progression agreed with the adjusted MBDA score when it was discordant with these measures. The rate of progression (ΔTSS > 5) increased from < 2% in the low (1–29) adjusted MBDA category to 16% in the high (45–100) category. A modeled risk curve indicated that risk increased continuously, exceeding 40% for the highest adjusted MBDA scores. Conclusion The adjusted MBDA score was validated as an RA disease activity measure that is prognostic for radiographic progression. The adjusted MBDA score was a stronger predictor of radiographic progression than conventional risk factors, including seropositivity, and its prognostic ability was not significantly improved by the addition of DAS28-CRP, CRP, SJC, or CDAI." @default.
- W3119188840 created "2021-01-18" @default.
- W3119188840 creator A5000754711 @default.
- W3119188840 creator A5023669540 @default.
- W3119188840 creator A5024484324 @default.
- W3119188840 creator A5031184565 @default.
- W3119188840 creator A5033668583 @default.
- W3119188840 creator A5040915422 @default.
- W3119188840 creator A5047117557 @default.
- W3119188840 creator A5052842332 @default.
- W3119188840 creator A5063586848 @default.
- W3119188840 creator A5072664936 @default.
- W3119188840 creator A5076871195 @default.
- W3119188840 creator A5081306729 @default.
- W3119188840 creator A5088387716 @default.
- W3119188840 date "2021-01-04" @default.
- W3119188840 modified "2023-10-14" @default.
- W3119188840 title "Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies" @default.
- W3119188840 cites W1761300068 @default.
- W3119188840 cites W1964095605 @default.
- W3119188840 cites W1983134858 @default.
- W3119188840 cites W2001390007 @default.
- W3119188840 cites W2009298607 @default.
- W3119188840 cites W2016601610 @default.
- W3119188840 cites W2037874703 @default.
- W3119188840 cites W2043597254 @default.
- W3119188840 cites W2063236332 @default.
- W3119188840 cites W2068797107 @default.
- W3119188840 cites W2075563270 @default.
- W3119188840 cites W2098279921 @default.
- W3119188840 cites W2099260383 @default.
- W3119188840 cites W2099334955 @default.
- W3119188840 cites W2104805321 @default.
- W3119188840 cites W2112482146 @default.
- W3119188840 cites W2116314748 @default.
- W3119188840 cites W2121095925 @default.
- W3119188840 cites W2124502604 @default.
- W3119188840 cites W2133022545 @default.
- W3119188840 cites W2141624058 @default.
- W3119188840 cites W2142219725 @default.
- W3119188840 cites W2156652067 @default.
- W3119188840 cites W2157995113 @default.
- W3119188840 cites W2158733279 @default.
- W3119188840 cites W2169772272 @default.
- W3119188840 cites W2177843344 @default.
- W3119188840 cites W2256563020 @default.
- W3119188840 cites W2514249865 @default.
- W3119188840 cites W2550726844 @default.
- W3119188840 cites W2567019529 @default.
- W3119188840 cites W2606169847 @default.
- W3119188840 cites W2768934367 @default.
- W3119188840 cites W2802347208 @default.
- W3119188840 cites W2859548373 @default.
- W3119188840 cites W2889130537 @default.
- W3119188840 cites W2897837561 @default.
- W3119188840 cites W2906042285 @default.
- W3119188840 cites W2916214174 @default.
- W3119188840 cites W2988345887 @default.
- W3119188840 cites W2999916750 @default.
- W3119188840 cites W3007319208 @default.
- W3119188840 cites W4210768724 @default.
- W3119188840 cites W4249063051 @default.
- W3119188840 doi "https://doi.org/10.1186/s13075-020-02389-4" @default.
- W3119188840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7784276" @default.
- W3119188840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33397438" @default.
- W3119188840 hasPublicationYear "2021" @default.
- W3119188840 type Work @default.
- W3119188840 sameAs 3119188840 @default.
- W3119188840 citedByCount "12" @default.
- W3119188840 countsByYear W31191888402021 @default.
- W3119188840 countsByYear W31191888402022 @default.
- W3119188840 countsByYear W31191888402023 @default.
- W3119188840 crossrefType "journal-article" @default.
- W3119188840 hasAuthorship W3119188840A5000754711 @default.
- W3119188840 hasAuthorship W3119188840A5023669540 @default.
- W3119188840 hasAuthorship W3119188840A5024484324 @default.
- W3119188840 hasAuthorship W3119188840A5031184565 @default.
- W3119188840 hasAuthorship W3119188840A5033668583 @default.
- W3119188840 hasAuthorship W3119188840A5040915422 @default.
- W3119188840 hasAuthorship W3119188840A5047117557 @default.
- W3119188840 hasAuthorship W3119188840A5052842332 @default.
- W3119188840 hasAuthorship W3119188840A5063586848 @default.
- W3119188840 hasAuthorship W3119188840A5072664936 @default.
- W3119188840 hasAuthorship W3119188840A5076871195 @default.
- W3119188840 hasAuthorship W3119188840A5081306729 @default.
- W3119188840 hasAuthorship W3119188840A5088387716 @default.
- W3119188840 hasBestOaLocation W31191888401 @default.
- W3119188840 hasConcept C11783203 @default.
- W3119188840 hasConcept C126322002 @default.
- W3119188840 hasConcept C141071460 @default.
- W3119188840 hasConcept C151956035 @default.
- W3119188840 hasConcept C185592680 @default.
- W3119188840 hasConcept C198451711 @default.
- W3119188840 hasConcept C2777575956 @default.
- W3119188840 hasConcept C2779134260 @default.
- W3119188840 hasConcept C2781197716 @default.
- W3119188840 hasConcept C36454342 @default.
- W3119188840 hasConcept C55493867 @default.
- W3119188840 hasConcept C71924100 @default.
- W3119188840 hasConceptScore W3119188840C11783203 @default.